Lancet Oncology publishes policy review on targeted oncology therapies and companion diagnostics testing by experts convened by AHF

The growth of the CDx sector has been significant in the past several years with much of the activity focused in the area of oncology.  AHF convened a panel of Brazilian experts on oncology and companion diagnostics to review existing barriers and develop practical recommendations concerning policy fixes for the use of companion diagnostics (CDx) and personalized medicines for oncology in Brazil. 

The resulting paper, entitled "Brazilian health-care policy for targeted oncology therapies and companion diagnostic testing," was published on July 27, 2016 in the Lancet Oncology.

 Click here for a link to the full article, and click here to see the press release.